The content delivery network companies have settled their decade-long dispute over a patent that was the focus of a Supreme Court ruling. A district court jury confirmed Limelight infringed the patent this June, with Akamai awarded $51 million damages
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
The Delhi High Court declined to stop Dr. Reddy’s from manufacturing Novo Nordisk’s drug, but will continue to hear the Danish company’s injunction application